Cycling Peptides: A Protocol Framework for Any Stack

Every peptide protocol has a lifecycle. Start. Run. Assess. Switch or rest. Repeat. The difference between someone who gets results and someone who burns out — or adapts — is usually not which peptide they chose, but how they cycled it.

Here's a framework that works across every stack category on Personalized Peptides.

Why Cycling Matters

Peptides are signaling molecules. They work by activating receptors and triggering cascades — hormone release, gene transcription, protein synthesis. Receptors adapt. Constant signaling produces diminishing returns: the same dose produces a weaker effect over time as receptor sensitivity declines or downstream pathways reach saturation.

Cycling solves two problems simultaneously: it maintains efficacy by preventing receptor adaptation, and it provides a structured assessment point — "after 8 weeks, are we seeing what we expected to see?" Without a defined cycle endpoint, you're running blind indefinitely.

Cycle Length by Category

Category	Typical Cycle	Rest Period	Example Compounds
Recovery (injury)	4–8 weeks	4–6 weeks	BPC-157, TB-500
Recovery (chronic)	8–12 weeks	4–6 weeks	BPC-157 + TB-500 combo
Weight Loss (GLP-1)	12–20 weeks	Titrate down, not off	Semaglutide, Tirzepatide, Retatrutide
GH Secretagogues	8–12 weeks	4 weeks	CJC-1295, Ipamorelin, Sermorelin
Longevity	8–12 weeks	4–8 weeks	Epitalon, SS-31, MOTS-c
Cognitive	4–8 weeks	2–4 weeks	SEMAX, Selank, Dihexa
Skin / Cosmetic	8–12 weeks	4 weeks	GHK-Cu, Melanotan-2

These are starting points, not rules. Individual response, goal severity, and DNA markers all shift these windows. A fast CYP metabolizer may need shorter cycles with more frequent assessment; a slow responder may need longer cycles to accumulate effect.

The Assessment Point

The end of every cycle is a decision point. Three possible paths:

Continue. Results are tracking, no side effects, still progressing. Extend the cycle by its original length and reassess.

Switch. Plateau reached. The peptide worked but it's done what it can. Switch to a compound with a different mechanism in the same category — e.g., from BPC-157 to TB-500 within recovery, or from semaglutide to tirzepatide within weight loss.

Rest. Full rest period with no peptides. Receptors reset. Reassess goals before the next cycle. This is underused — many users cycle continuously for months or years, accumulating receptor adaptation without realizing it.

Stack Cycling vs Solo Cycling

When peptides are stacked, cycle them together. Don't run one compound continuously while cycling another — the constant signal from one peptide can interfere with the rest-and-reset phase the other needs. The exception is stacks with different cycle lengths (e.g., a recovery peptide on an 8-week cycle alongside a longevity peptide on a 12-week cycle) — in these cases, align the rest periods to the longest cycle in the stack.

When Not to Cycle

Some peptides don't follow the cycle model. GLP-1 agonists for weight loss are typically titrated rather than cycled — dose increases over weeks, then maintenance dosing, with a taper-down rather than an abrupt stop. GHK-Cu topical formulations can be used continuously because the topical route doesn't produce the same systemic adaptation as injection.

The cycle framework applies most directly to injectable peptides with receptor-mediated mechanisms. Oral, topical, or non-receptor-mediated compounds follow different rules.

For category-specific protocols, see Building a Recovery Protocol and The GLP-1 Landscape. For the longevity category, NAD+ and Aging covers mitochondrial peptides and their cycle logic.